Johnny Nijm

CV

• Regional Hospital, Ryhov, Jönköping, Sweden 2005 —
• Consultant in cardiology and clinical physiology (since 2007)
• Deputy Head of Department. Clinical Physiology (since 2015)
• Lecturer, Medical Doctorate Program (since 2018)
• Head of operations at the department of Clinical Physiology (since September 2023)
• Medical Doctor, Highland Hospital, Eksjo, Sweden 2000 – 2005
• Specialty Training in Neurology (later changed to Cardiology).

Education

• Specialist in Clinical Physiology Jun 2010
• PhD Degree, University of Linköping Dec 2008
• Specialist in Cardiology Jun 2007
• Specialist in Internal Medicine Jun 2006
• Medical Doctorate Degree, University of Gothenburg Jun 2000

Other achievements

• During university studies (Gothenburg)
  Pre-clinical research in pharmacology, partly alcohol research and partly behavioural research with focus on the Dopamine and Serotonin systems.
• Infection and Immunology (University of Linköping)
  Thesis on Hypogammaglobulinemia.
• Docent courses, parts 1 & 2 (University of Linköping)
• Course in “the Academic Teacher” (University of Linköping)
• Course in “Sustainable Leadership” (University of Jönköping)
• Course in 3D TTE/TEE, Stockholm (Jan 2018)
• Course in 3D TTE/TEE, Copenhagen (Jan 2020)
• Process Manager, Cardiac Ultrasound, Clinical Physiology
• Supervisor for a Doctoral Student, Anders Lind
• Instructor course, Linköping
  Focus on knowledge and learning.
• Assistant Supervisor for Henning Clausen research project
  The aim of the project is to establish cardiovascular biomarker profiles in blood and saliva to assist in the assessment of critical congenital heart defects in new-borns and use new cardiovascular biomarkers and advanced echocardiography measurements in older children with congenital heart defects to better predict left- and right-sided re-modelling of the heart and thus optimize the timing and type of heart interventions in the future.
• Continued R&D in KAROS study with Patrick Karlström
  Prospective cardio-oncology study with insight into the heart muscle’s mechanism of damage due to cardio toxic cytotoxic drugs regarding echocardiographic changes, heart marker changes and inflammatory response.
  Analysis of primary results, spring 2024
  Inclusion ends 2024-07-01